secwatch.observer — SEC 8-K summary
======================================

Issuer:     KYNTRA BIO, INC. (KYNB)
CIK:        0000921299
Form:       8-K
Filed at:   2023-07-19T23:59:59+00:00
Accession:  0000950170-23-033458
Event type: other_material
Sentiment:  negative
Materiality: 0.65
Item codes: 2.05
LLM model:  deepseek-v4-flash:cloud@v2

FibroGen cuts US workforce 32% (104 employees); expects $13-15M charges
-----------------------------------------------------------------------

- Workforce reduction of ~32% (104 U.S. employees) approved July 14, 2023.
- Non-recurring charges of $13-15M for severance, notice pay, vacation, benefits.
- Plan expected to generate $30-35M in annual cost savings.
- Majority of charges in Q3 2023; reduction substantially complete by Q1 2024.
- Company expects existing cash, equivalents, investments to fund ops into 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/921299/000095017023033458/0000950170-23-033458-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/921299/000095017023033458/fgen-20230714.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-033458

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer